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Objectives We hypothesized that a greater 2-year decline in office-based functional performance measures would be asso-
ciated with greater mobility loss and mortality in people with peripheral arterial disease (PAD).
Background Associations of decline in functional performance with clinically important outcomes in patients with PAD are
unknown.
Methods A total of 440 men and women with PAD completed the 6-min walk test and measures of walking velocity at
baseline and annually for 2 years. Participants were categorized into tertiles according to their functional decline
between baseline and 2-year follow-up and were followed annually after the functional change assessment. Cox
proportional hazard models were used to assess relations between the 2-year change in functional performance
with later mortality and mobility loss, with adjustments for age, sex, race, ankle brachial index, comorbidities,
and other confounders.
Results A total of 102 participants (23.2%) died during a median follow-up of 44.5 months after functional change was
assessed. Of 319 participants without baseline mobility disability, 60 (18.8%) developed mobility loss after func-
tional change was assessed. Participants in the tertile with the greatest 6-min walk decline had the highest sub-
sequent mobility loss (hazard ratio [HR]: 3.50; 95% confidence interval [CI]: 1.56 to 7.85; p  0.002), all-cause
mortality (HR: 2.16; 95% CI: 1.28 to 3.64; p  0.004), and cardiovascular disease mortality (HR: 2.45; 95% CI:
1.08 to 5.54; p  0.031), compared with those with the smallest 6-min walk decline. Greater declines in fastest-
paced 4-m walking velocity were associated with higher mobility loss (p trend  0.018), all-cause mortality
(p trend  0.01), and cardiovascular mortality (p trend  0.004).
Conclusions Participants with PAD with declining functional performance are at increased risk for later mobility loss and
mortality. (J Am Coll Cardiol 2011;57:962–70) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.053Men and women with lower-extremity peripheral arterial
disease (PAD) have greater functional impairment, faster
functional decline, and higher all-cause and cardiovascular
disease (CVD) mortality, compared with individuals with-
out PAD (1–3). Previous studies have demonstrated that
baseline performance on office-based functional measures
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accepted September 28, 2010.predicts subsequent mobility loss and mortality in patients
with PAD (4,5).
It is unknown whether greater declines in office-based
functional performance measures predict increased subse-
quent mobility loss or mortality in PAD. Declining perfor-
mance may indicate deteriorating health associated with
increased risk of later outcomes. Among men and women
with PAD, we studied associations between 2-year change
in lower-extremity performance and subsequent mobility
loss and mortality, after the functional change was assessed.
Functional performance measures assessed included the
6-min walk test, walking velocity over 4 m at usual and
fastest pace, and the short physical performance battery
(SPPB). We hypothesized that participants with PAD with
greater declines in these functional performance measures
over a 2-year period would have higher subsequent rates of
mobility loss, all-cause mortality, and CVD mortality,
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February 22, 2011:962–70 Functional Decline and Outcomes in PADcompared with participants with PAD with less decline. In
secondary analyses, we assessed the relative value of baseline
functional performance versus 2-year change in functional
performance for predicting later mobility loss and mortality
in participants with PAD.
Methods
Participant identification. The institutional review boards
of Northwestern University and Catholic Health Partners
Hospital approved the protocol. Participants gave written
informed consent.
Participants were part of the WALCS (Walking and Leg
Circulation Study) and WALCS II prospective, observa-
tional studies designed to identify clinical characteristics
associated with functional decline and mortality in PAD
(2–7). Participants with PAD were identified from among
consecutive patients in 3 Chicago-area noninvasive vascular
laboratories. Participants in the WALCS cohort were en-
rolled between 1998 and 2000 and returned annually for up
to 8 follow-up visits. Newly identified participants with
PAD were enrolled between 2002 and 2004 as part of the
WALCS II cohort and returned annually for up to 4
follow-up visits. WALCS participants were age 55 years or
older at enrollment (2,3). Newly identified WALCS II
participants, enrolled 4 years after the WALCS cohort,
were age 59 years and older at enrollment (6). Participants
with PAD from the WALCS and WALCS II cohorts were
included in this study if they attended a baseline visit and at
least 2 annual follow-up visits and continued to be followed
for later mortality and/or mobility loss.
All participants had an ankle brachial index (ABI)0.90 at
their baseline visit (2–7). Exclusion criteria have been previ-
ously reported (6,7). Briefly, nursing home residents,
wheelchair-bound individuals, and lower-extremity amputees
were excluded. Potential participants with dementia, non-
English speakers, and those with recent major surgery were
excluded. Participants who underwent lower-extremity revas-
cularization during the first 2 years of the study, when change
in functional performance was evaluated, were excluded from
all analyses. Participants who underwent lower-extremity re-
vascularization after the assessment of functional change were
excluded from analyses of mobility loss.
ABI measurement. A handheld Doppler probe (Nicolet
Vascular Pocket Dop II, Nicolet Biomedical Inc, Golden,
Colorado) was used to obtain systolic pressures in the right and
left brachial, dorsalis pedis, and posterior tibial arteries (2–7).
Each pressure was measured twice. The ABI was calculated by
dividing the mean of the dorsalis pedis and posterior tibial
pressures in each leg by the mean of the 4 brachial pressures
(8). Average brachial pressures in the arm with the highest
ressure were used when one brachial pressure was higher than
he opposite brachial pressure in both measurement sets and
he 2 brachial pressures differed by 10 mm Hg or more in at
east 1 measurement set because subclavian stenosis was pos-
ible in such cases (9). Zero values (n  17) for the dorsalisedis or posterior tibial vessels
ere excluded from the ABI cal-
ulation. The lowest leg ABI was
sed in analyses.
hange in functional perfor-
ance. All participants under-
ent baseline measures of func-
ional performance and returned
nnually for 2 years for assess-
ent of change in functional
erformance. Change in func-
ional performance between
aseline and the 2-year follow-up was studied for its
ssociation with subsequent mobility loss and mortality,
ccurring after the 2-year change in functional performance
ssessment was assessed.
6-MIN WALK. Following a standardized protocol (10,11),
participants walked up and down a 100-foot hallway for 6
minutes after instructions to cover as much distance as
possible. The intraclass correlation coefficient for test-retest
reliability of the 6-min walk was 0.90 (p  0.001) in our
laboratory among 156 participants with PAD who com-
pleted the tests approximately 1 to 2 weeks apart (12).
4-M WALKING VELOCITY. Walking velocity was measured
with a 4-m walk performed at “usual” and “fastest” pace
(2–4,7). For the “usual”-paced walk, participants were
instructed to walk at their usual pace, “as if going down the street
to the store.” Each walk was performed twice. The faster
walk in each pair was used in analyses (2–4,7,13,14).
REPEATED CHAIR RISES. Participants sat in a straight-
backed chair with arms folded across their chest and stood
5 times consecutively as quickly as possible. Time to
complete 5 chair rises was measured (13,14).
STANDING BALANCE. Participants were asked to hold 3
ncreasingly difficult standing positions for 10 s each: stand-
ng with feet together side by side and parallel (side-by-side
tand), standing with feet parallel with the toes of one foot
djacent to and touching the heel of the opposite foot
semitandem stand), and standing with one foot directly in
ront of the other (tandem stand) (13,14).
SPPB. The SPPB combines data from the usual-paced 4-m
walking velocity, time to rise from a seated position 5 times,
and standing balance. Individuals receive a zero score for
each task they are unable to complete. Scores of 1 to 4 are
assigned for remaining tasks, based upon quartiles of per-
formance for more than 6,000 participants in the EPESE
(Established Populations for the Epidemiologic Study of
the Elderly) cohort (13,14). Scores are summed to obtain
the SPPB, ranging from 0 to 12.
Mobility measures. At baseline and subsequent follow-up
visits, participants were asked whether they were able to
walk one-quarter mile and whether they could climb up and
Abbreviations
and Acronyms
ABI  ankle brachial index
BMI  body mass index
CVD  cardiovascular
disease
PAD  peripheral arterial
disease
SPPB  short physical
performance batterydown 1 flight of stairs, selecting 1 of the following 3
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Functional Decline and Outcomes in PAD February 22, 2011:962–70response options for each measure: 1) “yes, on my own”;
2) “yes, with help”; or 3) ”no, not at all.” Participants
eligible for analyses of mobility loss were those who reported
the ability to walk one-quarter mile and climb up and down
1 flight of stairs on their own at the baseline, first annual
follow-up, and second annual follow-up visits. Mobility loss
was defined as becoming unable to walk one-quarter mile or
walk up and down 1 flight of stairs without assistance after
the second annual follow-up visit (5,15,16).
Death. We used the Social Security Administration Death
Index to search for deaths through May 23, 2009. Informa-
tion on deaths was also obtained from family members,
proxies, and primary care physicians. Death certificates were
obtained from the state in which death occurred or from the
patient’s medical record. Deaths owing to CVD were those with
International Classification of Disease-10 codes in the range
I01.0 through I99.9, including deaths owing to coronary
heart disease, stroke, peripheral vascular disease, and other
CVD (4).
Comorbidities. Comorbidities assessed included diabetes,
angina, myocardial infarction, heart failure, cancer, chronic
lung disease, lower-extremity arthritis, spinal stenosis, spi-
nal disk disease, and stroke. Disease-specific algorithms that
combine data from patient report, medical record review,
medications, laboratory values, and a questionnaire com-
pleted by the participant’s primary care physician were used
to verify and document baseline comorbidities, based on
criteria previously developed (17). American College of
Rheumatology criteria were used to diagnose knee and hip
osteoarthritis (18,19).
Medication identification. The study principal investiga-
tor (M.M.M.), blinded to all other patient data, reviewed
lists of medications at the baseline visit and identified
presence versus absence of statin use and use of PAD-
related medications (cilostazol or pentoxifylline).
Other measures. Body mass index (BMI) was calculated as
weight (kg)/height2 (m2). Cigarette smoking history was
etermined from patient report. For measurement of phys-
cal activity, participants were asked, “During the last week,
ow many city blocks or their equivalent did you walk?”
20). This measure of patient-reported physical activity is
ighly correlated with vertical accelerometer-measured
hysical activity in participants with PAD (20).
tatistical analyses. Baseline characteristics between par-
icipants with PAD with and without mobility loss and
etween survivors and decedents were compared using
eneral linear models for continuous variables and chi-
quare tests for categoric variables, adjusting for age. We
ssumed a linear association of age with continuous study
ariables. We used logistic regression to adjust for age for
ategoric variables.
We did not observe a threshold effect for the associations of
hange in functional performance measures with each study
utcome. Therefore, participants were categorized into tertiles
ccording to their change in each functional performance
easure between baseline and 2-year follow-up. The decision wo classify participants into tertiles was made in an a priori
ashion. Proportional hazards analyses were used to compare
ifferences in mobility loss, all-cause mortality, and CVD
ortality across tertiles of 2-year change in functional perfor-
ance. The third tertile represented the least functional de-
line, and the first tertile represented the greatest functional
ecline. Proportional hazards analyses were performed to
etermine associations of each tertile with mobility loss, all-
ause mortality, and CVD mortality, adjusting for age, sex,
ace, and baseline functional performance (model I). These
roportional hazards analyses were repeated with additional
djustment for comorbidities, cigarette smoking (pack-years),
MI, ABI, physical activity, relevant medications, and study
ohort (WALCS vs. WALCS II) (model II). Ordinal values
i.e., 1, 2, 3) were entered for each tertile in the analyses. For
he models relating change in functioning to mobility loss,
omorbidities included in model II were diabetes, angina,
yocardial infarction, heart failure, cancer, chronic lung dis-
ase, lower-extremity arthritis, spinal stenosis, spinal disk
isease, and stroke. For models relating change in functioning
o mortality, comorbidities included in model II were diabetes,
ngina, myocardial infarction, heart failure, cancer, chronic
ung disease, and stroke. For the models relating change in
unctioning to mobility loss, relevant medications included in
odel II were cilostazol, pentoxifylline, and statins. For the
odels relating change in functioning to mortality, relevant
edications included in model II were statins. Proportional
azards models were repeated in which a standardized regres-
ion coefficient was used in place of tertile measurements for
he change in functioning variable. These analyses using
tandardized regression coefficients allowed us to compare the
agnitude of the association of the change in functioning
ariable with the variable for baseline functional performance.
or all proportional hazards models, we tested for the propor-
ional hazards assumption (21). The proportional hazards
ssumption was valid through the first 72 months of follow-up
fter baseline testing. Therefore, our models were truncated at
2-month follow-up. Analyses were performed using SAS
tatistical software (PHREG procedures, version 9.1, SAS
nstitute Inc., Cary, North Carolina).
esults
total of 440 participants with PAD were eligible for the
ortality outcome analyses, and 319 were eligible for the
obility loss analyses (Fig. 1). There were no differences in
he prevalence of men (55.0% vs. 56.8%) or African Amer-
cans (18.5% vs. 16.6%) between potential participants who
ere ineligible versus eligible, respectively. However, ineli-
ible participants had poorer 6-min walk performance
1,017 feet vs. 1,174 feet; p  0.001), slower usual-paced
-m walking velocity (0.83 m/s vs. 0.89 m/s; p  0.01),
slower fast-paced 4-m walking velocity (1.13 m/s vs. 1.21
m/s; p 0.01), lower SPPB scores (9.26 vs. 9.83; p 0.01),
nd lower ABI values (0.62 vs. 0.66; p  0.01), compared
ith eligible participants.
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February 22, 2011:962–70 Functional Decline and Outcomes in PADOverall median follow-up after baseline measures was 70.5
months (interquartile range: 50.0 to 97.0 months). Median
follow-up for study outcomes after assessment of 2-year change
in functioning was 44.5 months (interquartile range: 26.0 to
73.0 months). Death certificates were obtained for 92 (90.2%)
decedents. Thirty-nine deaths (38.2%) were due to CVD, and
20 (19.6%) were due to cancer.
Table 1 shows baseline characteristics of participants with
AD according to the outcomes of mobility loss and
ortality. Adjusting for age, participants with PAD who
eveloped mobility loss included higher proportions of
omen and participants with diabetes mellitus. Participants
ith PAD who developed mobility loss had poorer baseline
unctional performance compared with those who remained
ree of mobility disability during follow-up. Adjusting for
ge, participants who died during follow-up included higher
roportions of participants with history of angina, heart
ailure, and diabetes mellitus compared with survivors. At
aseline, decedents had poorer baseline functional perfor-
ance compared with survivors (Table 1).
Adjusting for age, sex, race, and baseline functional perfor-
Figure 1 Depiction of Eligible Participants From the WALCS an
*Excluded because they did not return annually for 2 years for functional assessm
the first 2 years of follow-up (n  48), they were lost to follow-up after their 2-year
adjusted models (n  6). †Excluded because they met criteria for mobility disabili
mobility status during follow-up (n  45). PAD  peripheral arterial disease; WALCance (model I), greater declines between baseline and 2-year afollow-up in the usual-paced walking velocity (p trend
0.001), fast-paced walking velocity (p trend  0.014), and
PPB scores (p trend 0.001) were each associated with
igher rates of mobility loss after the functional change
ssessment (Table 2). After additional adjustment for comor-
idities, BMI, relevant medications, smoking, study cohort
WALCS vs. WALCS II), physical activity, and ABI, greater
-year declines in the 6-min walk, usual- and fast-paced 4-m
alking velocity, and SPPB score were associated with a higher
ate of subsequent mobility loss (Table 2).
In analyses adjusting for age, sex, race, and baseline func-
ional performance (model I), greater declines between baseline
nd 2-year follow-up in 6-min walk performance (p trend
0.001) and fast-paced walking velocity (p trend 0.001)
ere associated with higher all-cause mortality during subse-
uent follow-up (Table 2, model I). After additional adjust-
ent for comorbidities, relevant medications, BMI, smoking,
tudy cohort, physical activity, and ABI (model II), greater
eclines in the 6-min walk test (p trend  0.001), usual-paced
-m walking velocity (p trend  0.332), and fast-paced 4-m
alking velocity (p trend0.001) were associated with higher
LCS II Cohorts
ter baseline (n  198), they underwent lower-extremity revascularization during
ional change assessment (n  8), or they had missing variables in the fully
een baseline and 2-year follow-up (n  76) or they were missing data on their
alking and Leg Circulation Study.d WA
ent af
funct
ty betw
S  Wll-cause mortality (Table 2, model II).
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Functional Decline and Outcomes in PAD February 22, 2011:962–70Adjusting for age, sex, race, and baseline functional
performance (model I), greater declines between baseline
and 2-year follow-up in the fast-paced walking velocity
(p trend  0.001) and SPPB scores (p trend  0.041) were
each associated with higher rates of subsequent CVD
mortality (Table 2). After additional adjustment for comor-
bidities, BMI, smoking, relevant medications, study cohort,
physical activity, and ABI, greater declines in the 6-min
walk (p trend  0.017) and fast-paced walking velocity (p
trend  0.004) were each associated with higher rates of
CVD mortality during follow-up after the functional
change was assessed (Table 2, model II).
Table 3 shows standardized hazard ratios from statistical
models including associations of both baseline functional
Age-Adjusted Associations of Study Characteristics With MortalityTable 1 Age-Adjusted Associations of Study Characteristics W
Participants Free of
Mobility Disability
at Baseline
(n  319)
Particip
Free
Disa
F
(
Mobility Di
Ankle brachial index 0.67 (0.14)
Body mass index (kg/m2) 27.23 (4.96) 2
Male 60.82
African American 15.99
Current smoker 19.12
Angina 29.47
Myocardial infarction 22.88
Pulmonary disease 28.21
Cancer 15.67
Heart failure 18.18
Diabetes mellitus 28.84
6-min walk (feet) 1,258.46 (323.57) 1,30
Usual-pace 4-m walking velocity (m/s) 0.94 (0.19)
Fastest-pace 4-m walking velocity (m/s) 1.28 (0.25)
SPPB score (0–12; 12  best) 10.34 (1.87) 1
All-Cause M
Baseline Characteristics
(n  440)
Ankle brachial index 0.66 (0.15)
Body mass index (kg/m2) 27.52 (5.49)
Male 56.82
African American 16.59
Current smoker 15.68
Angina 31.14
Myocardial infarction 23.64
Pulmonary disease 32.73
Cancer 15.45
Heart failure 21.36
Diabetes mellitus 32.05
6-min walk (feet) 1,173.61 (369.02)
Usual-pace 4-m walking velocity (m/s) 0.89 (0.21)
Fastest-pace 4-m walking velocity (m/s) 1.21 (0.29)
SPPB score (0–12; 12  best) 9.83 (2.36)
Data are shown as mean (SE) or %.
PAD  peripheral arterial disease; SPPB  short physical performance battery.performance measures and change in each functional per- aformance measure with study outcomes. These analyses,
using standardized hazard ratios, allow direct comparison of
baseline functional performance measures and change in
functional performance as predictors of study outcomes.
Adjusting for age, sex, race, comorbidities, ABI, BMI,
smoking, physical activity, relevant medications, and study
cohort, poorer baseline 6-min walk performance (p 
.001) and greater decline in 6-min walk performance (p 
.007) were each associated with increased rates of mobility
oss during follow-up after the functional change assessment
Table 3, model II). Similarly, for the remaining functional
easures, poorer baseline performance and greater declines
n performance were each associated independently and
ignificantly with higher rates of mobility loss in fully
Mobility Loss Among Participants With PADortality and Mobility Loss Among Participants With PAD
emaining
obility
During
-Up
59)
Participants Who Developed
Mobility Loss
During Follow-Up
(n  60)
p Value Comparing
Participants With
vs. Without Mobility
Disability During Follow-Up
y Outcome
0.01) 0.68 (0.02) 0.399
0.31) 28.12 (0.64) 0.081
8 42.85 0.003
5 17.42 0.562
7 15.67 0.972
6 27.54 0.67
7 31.34 0.097
5 31.34 0.405
5 12.1 0.369
9 17.05 0.867
3 43.14 0.002
19.16) 1,023.53 (39.05) 0.001
0.01) 0.80 (0.02) 0.001
0.01) 1.07 (0.03) 0.001
0.10) 8.58 (0.22) 0.001
y Outcome
Survivors
(n  338)
Decedents
(n  102)
p Value Comparing
Decedents and Survivors
0.67 (0.01) 0.64 (0.01) 0.084
27.62 (0.29) 27.21 (0.54) 0.508
54.5 65.07 0.064
15.39 19.39 0.352
12.8 14.67 0.635
26.77 45.09 0.001
21.4 30.74 0.055
30.81 38.95 0.132
16.04 13.01 0.456
17.71 33.51 0.001
25.95 47.83 0.001
,199.57 (19.48) 1,086.74 (35.88) 0.006
0.91 (0.01) 0.86 (0.02) 0.040
1.22 (0.01) 1.18 (0.03) 0.257
9.98 (0.12) 9.26 (0.23) 0.005andith M
ants R
of M
bility
ollow
n  2
sabilit
0.66 (
6.87 (
64.2
14.3
15.8
30.3
21.0
25.8
16.7
17.9
21.7
7.84 (
0.97 (
1.32 (
0.66 (
ortalit
1djusted analyses (Table 3, model II).
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b
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February 22, 2011:962–70 Functional Decline and Outcomes in PADIn analyses adjusting for age, sex, and race, and
including both baseline performance measures and
changes in performance measures, poorer baseline per-
formance on each functional measurement and greater
decline in performance in each functional measure were
each associated significantly with higher all-cause mor-
tality (Table 3, model I). After additional adjustment for
comorbidities, ABI, BMI, smoking, relevant medica-
Adjusted Associations of 2-Year Change in Functional PerformanceWith Mortality and Mobility Loss Among Participants With PADTable 2 Adjusted Associations of 2-Ye Change in Functio alWith Mortality and Mobility Loss Among Participants W
Functional
Performance Measure Tertiles
Mod
Standardized HR (95% CI)
Mobility loss (n  319)
6-min walk Tertile 1 1.85 (0.99–3.47)
Tertile 2 1.79 (0.88–3.63)
Tertile 3 1.00 (reference)
4-m velocity, usual pace Tertile 1 3.40 (1.64–7.05)*
Tertile 2 1.95 (1.07–3.54)
Tertile 3 1.00 (reference)
4-m velocity, fast pace Tertile 1 2.35 (1.17–4.74)‡
Tertile 2 1.87 (0.98–3.57)
Tertile 3 1.00 (reference)
SPPB score Tertile 1 4.43 (1.97–9.96)*
Tertile 2 1.70 (0.66–4.37)
Tertile 3 1.00 (reference)
All-cause mortality (n  440)
Tertile 1 2.28 (1.37–3.80)*
6-min walk Tertile 2 1.18 (0.67–2.08)
Tertile 3 1.00 (reference)
4-m velocity, usual pace Tertile 1 1.54 (0.94–2.53)
Tertile 2 1.02 (0.62–1.67)
Tertile 3 1.00 (reference)
4-m velocity, fast pace Tertile 1 2.60 (1.51–4.48)*
Tertile 2 1.85 (1.07–3.19)†
Tertile 3 1.00 (reference)
SPPB score Tertile 1 1.62 (0.93–2.81)
Tertile 2 0.95 (0.51–1.76)
Tertile 3 1.00 (reference)
Cardiovascular mortality (n  445)
Tertile 1 2.21 (1.01–4.85)§
6-min walk Tertile 2 0.54 (0.19–1.53)
Tertile 3 1.00 (reference)
4-m velocity, usual pace Tertile 1 1.91 (0.85–4.24)
Tertile 2 0.90 (0.38–2.11)
Tertile 3 1.00 (reference)
4-m velocity, fast pace Tertile 1 6.97 (2.31–21.05)*
Tertile 2 2.94 (0.92–9.42)
Tertile 3 1.00 (reference)
SPPB score Tertile 1 2.67 (0.96–7.49)
Tertile 2 1.51 (0.47–4.78)
Tertile 3 1.00 (reference)
*p 0.01. †p 0.01. ‡p 0.0169. §p 0.047. p 0.0277. Model I adjusted for age, sex, and
bodymass index, smoking, relevantmedications, and study cohort. For model II relating change in fu
heart failure, cancer, chronic lung disease, lower-extremity arthritis, spinal stenosis, spinal disk dis
II were diabetes, angina, myocardial infarction, heart failure, cancer, chronic lung disease, and strok
and pentoxifylline. For model II relating change in functioning to mortality, relevant medications w
CI  confidence interval; HR  hazard ratio. Other abbreviations as in Table 1.tions, study cohort, and physical activity, poorer baseline c6-min walk performance (p  0.005) and greater decline
in 6-min walk performance (p  0.011) were each
associated independently with higher all-cause mortality
(Table 3, model II). In fully adjusted analyses, greater
decline in the fast-paced 4-m walking velocity (p 
.003) and greater decline in SPPB scores (p  0.032)
etween baseline and 2-year follow-up were associated
ith increased all-cause mortality (Table 3, model II). In
suresrmance Measures
PAD
Model II
p Trend Value Standardized HR (95% CI) p Trend Value
3.50 (1.56–7.85)*
0.054 3.03 (1.28–7.15)† 0.003
1.00 (reference)
3.67 (1.59–8.48)*
0.001 2.45 (1.23–4.88)† 0.001
1.00 (reference)
0.014 2.45 (1.15–5.23)‡ 0.018
2.80 (1.32–5.91)*
1.00 (reference)
5.57 (2.20–14.12)*
0.001 1.99 (0.71–5.57) 0.0002
1.00 (reference)
2.16 (1.28–3.64)*
0.001 0.93 (0.51–1.70) 0.001
1.00 (reference)
1.31 (0.77–2.23)
0.098 1.01 (0.61–1.67) 0.332
1.00 (reference)
0.001 2.14 (1.20–3.79)* 0.010
1.61 (0.91–2.85)
1.00 (reference)
1.42 (0.79–2.54)
0.055 0.87 (0.46–1.65) 0.170
1.00 (reference)
2.45 (1.08–5.54)
0.017 0.48 (0.16–1.44) 0.017
1.00 (reference)
1.92 (0.78–4.73)
0.111 1.01 (0.41–2.44) 0.176
1.00 (reference)
0.001 4.86 (1.53–15.47)* 0.004
2.51 (0.76–8.30)
1.00 (reference)
1.67 (0.56–5.02)
0.041 1.33 (0.40–4.39) 0.346
1.00 (reference)
odel II adjusted for covariates in model I and ankle brachial index, comorbidities, physical activity,
ng tomobility loss, comorbidities included inmodel II were diabetes, angina, myocardial infarction,
d stroke. For model II relating change in functioning to mortality, comorbidities included in model
odel II relating change in functioning tomobility loss, relevant medications were statins, cilostazol,
tins.MeaPerfo
ith
el I
race. M
nctioni
ease, an
e. For m
ere staontrast, slower baseline walking velocity and lower
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mortality in fully adjusted analyses (Table 3, model II).
In analyses adjusting for age, sex, and race and includ-
ing both baseline performance measures and changes in
performance measures, poorer baseline 6-min walk per-
formance (p  0.003) was associated significantly with
higher CVD mortality (Table 3, model I). In these
analyses, greater decline in 6-min walk performance (p 
0.035), usual-paced 4-m walking velocity (p  0.016),
and SPPB scores (p  0.013) were each associated
significantly with higher CVD mortality. In fully ad-
justed analyses, only greater decline in fast-paced 4-m
walking velocity (p  0.001) was associated with higher
CVD mortality (Table 3, model II).
Discussion
Results reported here demonstrate that decline in any 1 of 4
office-based functional performance measures over a 2-year
Adjusted Comparisons of Baseline Functional Performance MeasurFunctional Perfo ma ce Measures With Mortality and Mobility LossTable 3 Adjusted C mp risons of Baseline Functio al PerformaFunctional Performance Measures With Mortality and
Functional
Performance Measure Measurement
S
Mobility loss (n  324)
6-min walk 2-yr change in performance 0
Baseline value 0
4-m velocity, usual pace 2-yr change in performance 0
Baseline value 0
4-m velocity, fast pace 2-yr change in performance 0
Baseline value 0
SPPB score 2-yr change in performance 0
Baseline value 0
All-cause mortality (n  446)
6-min walk 2-yr change in performance 0
Baseline value 0
4-m velocity, usual pace 2-yr change in performance 0
Baseline value 0
4-m velocity, fast pace 2-yr change in performance 0
Baseline value 0
SPPB score 2-yr change in performance 0
Baseline value 0
Cardiovascular disease mortality (n  446)
6-min walk 2-yr change in performance 0
Baseline value 0
4-m velocity, usual pace 2-yr change in performance 0
Baseline value 0
4-m velocity, fast pace 2-yr change in performance 0
Baseline value 0
SPPB score 2-yr change in performance 0
Baseline value 0
Model I adjusted for age, sex, and race. Model II adjusted for covariates in model I and ankle bra
cohort. For model II relating change in functioning to mobility loss, comorbidities included in model
arthritis, spinal stenosis, spinal disk disease, and stroke. For model II relating change in functioning
cancer, chronic lung disease, and stroke. For model II relating change in functioning to mobility
functioning to mortality, relevant medications were statins.
Abbreviations as in Tables 1 and 2.period is associated with an increased rate of subsequentmobility loss in participants with PAD, even after control-
ling for age, comorbidities, medications, ABI, physical
activity, and other potential confounders. Greater decline in
6-min walk performance and fastest-paced 4-m walking ve-
locity were also associated with increased all-cause mortality,
compared with lesser declines in these functional performance
measures. Finally, greater decline in 6-min walk performance
was associated with higher CVD mortality.
Functional performance measures, such as the 6-min
walk test and walking velocity over 4 m, are reliable,
objective measures of lower-extremity performance that can
be administered in the office setting. They require a short
amount of time and only a stopwatch to administer. Based
on findings reported here, clinicians can potentially use
serial, annual measures of functional performance over 2
years of follow-up to identify people with PAD who are at
increased risk for mobility loss and mortality.
To our knowledge, no prior studies have assessed associ-
d 2-Year Change inng Particip ts With PADMeasu es and 2-Year Change in
lity Loss Among Participants With PAD
Model I Model II
rdized HR
% CI) p Value
Standardized HR
(95% CI) p Value
.76–0.96) 0.01 0.82 (0.71–0.95) 0.007
.30–0.51) 0.001 0.31 (0.21–0.47) 0.001
.63–0.87) 0.001 0.78 (0.66–0.92) 0.003
.15–0.35) 0.001 0.21 (0.12–0.35) 0.001
.67–0.89) 0.001 0.80 (0.69–0.92) 0.002
.22–0.43) 0.001 0.29 (0.19–0.46) 0.001
.64–0.85) 0.001 0.70 (0.59–0.82) 0.001
.27–0.44) 0.001 0.28 (0.20–0.40) 0.001
.81–0.97) 0.007 0.89 (0.81–0.97) 0.011
.49–0.76) 0.001 0.69 (0.53–0.90) 0.005
.80–0.99) 0.026 0.93 (0.84–1.03) 0.166
.54–0.86) 0.001 0.86 (0.66–1.11) 0.237
.74–0.91) 0.001 0.85 (0.77–0.95) 0.003
.55–0.87) 0.001 0.84 (0.64–1.09) 0.179
.79–0.97) 0.012 0.88 (0.79–0.99) 0.032
.55–0.85) 0.001 0.80 (0.62–1.04) 0.094
.75–0.99) 0.035 0.88 (0.75–1.02) 0.096
.41–0.83) 0.003 0.72 (0.45–1.14) 0.161
.71–0.97) 0.016 0.86 (0.72–1.02) 0.090
.47–1.02) 0.062 0.93 (0.60–1.43) 0.738
.63–0.85) 0.001 0.75 (0.63–0.90) 0.001
.48–1.00) 0.052 0.96 (0.60–1.54) 0.875
.69–0.96) 0.013 0.87 (0.72–1.05) 0.144
.49–1.02) 0.067 0.95 (0.60–1.49) 0.809
dex, comorbidities, physical activity, body mass index, smoking, relevant medications, and study
diabetes, angina, myocardial infarction, heart failure, cancer, chronic lung disease, lower-extremity
ality, comorbidities included in model II were diabetes, angina, myocardial infarction, heart failure,
elevant medications were statins, cilostazol, and pentoxifylline. For model II relating change ines anAmonce
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February 22, 2011:962–70 Functional Decline and Outcomes in PADmobility loss or mortality in participants with PAD. We
previously reported that poorer baseline 6-min walk perfor-
mance, slower baseline usual- and fastest-paced 4-m walk-
ing velocity, and lower baseline SPPB scores were associated
with higher rates of mobility loss among participants with
PAD over a 50-month follow-up (5). We also reported
that poorer baseline 6-min walk performance and slower
usual- and fastest-paced 4-m walking velocity were asso-
ciated with higher mortality among participants with
PAD (4). The current study demonstrated that for all
unctional performance measures evaluated, both poorer
aseline functional performance and greater decline in
unctional performance are associated significantly and
ndependently with increased rates of mobility loss, even
fter adjusting for potential confounders such as comor-
idities, ABI, and physical activity. Similarly, both
oorer baseline 6-min walk performance and greater
ecline in 6-min walk performance were associated with
igher all-cause mortality in participants with PAD.
owever, our results suggest that declines in fast-paced
alking velocity and SPPB score are more predictive of
ll-cause mortality than baseline measures of fast-paced
alking velocity and SPPB score, respectively.
Decline in functional performance is likely to predict
obility loss and mortality if it is a more sensitive measure
f deteriorating global health than measures such as comor-
idities or ABI. Declines in functional performance mea-
ures may be sensitive to progression of comorbid diseases
nd/or progression of systemic atherosclerosis, which in
urn may influence risk of mobility loss and mortality.
urther study is needed to determine whether preventing
unctional decline can protect against mobility loss and
ortality among individuals with PAD.
In unadjusted analyses, women with PAD had higher
ates of mobility loss than men with PAD (Table 1).
owever, we did not observe any interactions of sex on the
ssociations of decline in functional performance with
obility loss or mortality (data not shown). Further study is
eeded to establish sex differences in functional decline
mong men and women with PAD.
tudy limitations. First, data were observational. Associa-
tions of decline in functional performance with adverse
outcomes should not be construed as causal. Second, a priori
we selected functional performance over a 2-year follow-up
as the independent variable of interest for these analyses.
Our findings may not be generalizable to participants with
PAD without 2 years of functional performance measures.
Third, based on our exclusion criteria, our findings are not
generalizable to participants with PAD who undergo lower-
extremity revascularization during the 2-year measurement
of change in functioning. Fourth, we used death certificates
to ascertain CVD death, which may be associated with some
misclassification as compared with adjudicated cause of
death (22).Conclusions
Two-year declines in 6-min walk, usual- and fast-paced
walking velocity, and SPPB score predicted mortality and/or
mobility loss in participants with PAD. Further study is
needed to determine whether exercise and other interven-
tions that prevent functional decline are protective against
mobility loss and mortality in patients with PAD.
Reprint requests and correspondence: Dr. Mary M. McDer-
mott, Northwestern University Feinberg School of Medicine, 750
North Lake Shore Drive, 10th Floor, Chicago, Illinois 60611.
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